Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Ankylosing spondylitis and mesenchymal stromal/stem cell therapy: a new therapeutic approach

(2019) Ankylosing spondylitis and mesenchymal stromal/stem cell therapy: a new therapeutic approach. Biomedicine and Pharmacotherapy.

Full text not available from this repository.

Official URL:


Ankylosing spondylitis (AS) is an inflammatory rheumatoid disease categorized within spondyloarthropathies (SpA) and manifested by chronic spinal arthritis. Several innate and adaptive immune cells and secreted-mediators have been indicated to play a role in AS pathogenesis. Considering the limitations of current therapeutic approaches (NSAIDs, glucocorticoids, DMARDs and biologic drugs), finding new treatments with fewer side effects and high therapeutic potentials are required in AS. Mesenchymal stem cells (MSCs) with considerable immunomodulatory and regenerative properties could be able to attenuate the inflammatory responses and help tissue repair by cell-to-cell contact and secretion of soluble factors. Moreover, MSCs do not express HLA-DR, which renders them a favorable therapeutic choice for transplantation in immune-mediated disorders. In the present review, we describe immunopathogenesis and current treatments restrictions of AS. Afterwards, immunomodulatory properties and applications of MSCs in immune-mediated disorders, as well as recent findings of clinical trials involving mesenchymal stem cell therapy (MSCT) in ankylosing spondylitis, will be discussed in detail. Additional studies are required to investigate several features of MSCT such as cell origin, dosage, administration route and, specifically, the most suitable stage of disease for ideal intervention. © 2018 Elsevier Masson SAS

Item Type: Article
Keywords: HLA DR antigen, adaptive immunity; ankylosing spondylitis; antigen expression; cell regeneration; human; immunocompetent cell; immunomodulation; immunopathogenesis; inflammation; innate immunity; mediator release; mesenchymal stem cell transplantation; mesenchymal stroma cell; priority journal; Review; tissue repair; animal; ankylosing spondylitis; clinical trial (topic); cytology; mesenchymal stem cell; mesenchymal stem cell transplantation; procedures; rheumatoid arthritis, Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Spondylitis, Ankylosing
Page Range: pp. 1196-1205
Journal or Publication Title: Biomedicine and Pharmacotherapy
Volume: 109
Publisher: Elsevier Masson SAS
Identification Number: 10.1016/j.biopha.2018.10.137
ISSN: 07533322
Depositing User: مهندس جمال محمودپور

Actions (login required)

View Item View Item